HIV Infection
📧 Sign up to get email alerts when something new happens for HIV Infection.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2019-12-16Clinical Trial Update: Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients [Phase 4]
Phase 4 trial evaluating sirolimus and maraviroc on CCR5 expression and HIV-1 reservoir in HIV-infected kidney transplant recipients has bee…
-
FDA approval · 2019-12-13FDA Approved: TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Tenofovir disoproxil fumarate from Aurobindo Pharma Limited. The approval covers this generic fo…
-
FDA approval · 2019-12-13FDA Approved: LAMIVUDINE AND ZIDOVUDINE — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for Macleods' Lamivudine and Zidovudine fixed-dose combination product (ANDA090679) used to treat HI…
-
FDA approval · 2019-12-13FDA Approved: ABACAVIR — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' supplemental application for ABACAVIR (abacavir). This action confirms approval of a supplemental submi…
-
CLINICAL_TRIALS trial_result · 2019-12-13Clinical Trial Update: Video Information Provider for HIV-Associated Non-AIDS (VIP-HANA) Symptoms [NA]
A completed clinical trial studying a video information provider for HIV-associated non-AIDS symptoms; results posted in 2019.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-12-12FDA Approved: ABACAVIR — Supplemental Application (Cipla USA Inc.)
The FDA approved a supplemental application for abacavir from Cipla USA Inc., representing an approved supplement to an existing abacavir pr…
-
FDA approval · 2019-12-10FDA Approved: NEVIRAPINE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for Nevirapine submitted by Aurobindo Pharma Limited (ANDA077521).
-
CLINICAL_TRIALS trial_result · 2019-12-05Clinical Trial Update: Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years [Phase 3]
Phase 3 trial evaluating switching virologic regimens to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected partici…
-
CLINICAL_TRIALS trial_result · 2019-12-05Clinical Trial Update: Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in Co-infected HIV/HCV Patients [Phase 4]
Phase 4 trial comparing hepatic safety of Kaletra-based vs Nevirapine-based antiretroviral regimens in HIV/HCV co-infected patients; study t…
-
CLINICAL_TRIALS research · 2019-12-05Clinical Trial Update: Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (> 3 Years) With Lopinavir / Ritonavir Monotherapy [Phase 4]
A Phase 4 trial comparing virologic efficacy in CSF and neurocognitive state for HIV-1 patients on long-term lopinavir/ritonavir monotherapy…
-
CLINICAL_TRIALS trial_result · 2019-12-04Clinical Trial Update: Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+ [Phase 3]
A Phase 3 randomized trial evaluated duloxetine for fibromyalgia in patients with HIV-1 infection; the study is completed.
-
CLINICAL_TRIALS trial_result · 2019-12-04Clinical Trial Update: Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression [Phase 3]
A Phase 3 trial evaluating the impact of intensified raltegravir (MK-0518) on HIV-1 viral latency in patients who already had complete viral…
-
FDA label_change · 2019-12-03FDA Approved: DESCOVY — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for DESCOVY (emtricitabine and tenofovir alafenamide) from Gilead Sciences, Inc., resulting in a lab…
-
FDA approval · 2019-12-03FDA Approved: ODEFSEY — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for ODEFSEY (emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide) submitted by G…
-
FDA approval · 2019-11-27FDA Approved: COMPLERA — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for COMPLERA (emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate) submi…
-
CLINICAL_TRIALS trial_result · 2019-11-26Clinical Trial Update: Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services [Phase 2, Phase 3]
Phase 2/3 trial assessing implementation effectiveness and safety of delivering Tenofovir gel through family planning services for HIV preve…
-
CLINICAL_TRIALS trial_result · 2019-11-25Clinical Trial Update: Study to Evaluate a HIV Drug for the Treatment of HIV Infection [Phase 2]
Phase 2 trial update evaluating an HIV drug for the treatment of HIV infection has completed with results posted.
-
FDA approval · 2019-11-20FDA Approved: TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Chartwell RX, LLC.)
FDA approved a supplemental application for Tenofovir disoproxil fumarate tablets from Chartwell RX, LLC. This approval authorizes the marke…
-
CLINICAL_TRIALS trial_result · 2019-11-20Clinical Trial Update: Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed [Phase 3]
Phase 3 trial evaluating switching to fixed-dose combination B/F/TAF in virologically suppressed adults with HIV-1 infection.
-
CLINICAL_TRIALS trial_result · 2019-11-20Clinical Trial Update: The Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age [Phase 4]
Phase 4 trial update on safety, pharmacokinetics, and efficacy of raltegravir in HIV-infected patients aged 60 and over.
-
FDA approval · 2019-11-20FDA Approved: FOSAMPRENAVIR CALCIUM — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved the original ANDA for Fosamprenavir Calcium (generic) from Sun Pharmaceutical Industries, for treatment of HIV infection in com…
-
FDA approval · 2019-11-19FDA Approved: TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Strides Pharma Science Limited)
FDA approved a supplemental application for tenofovir disoproxil fumarate from Strides Pharma Science Limited, updating/expanding the approv…
-
CLINICAL_TRIALS trial_result · 2019-11-19Clinical Trial Update: Impact of Everolimus on HIV Persistence Post Kidney or Liver Transplant [Phase 4]
Phase 4 trial evaluating the impact of Everolimus on HIV persistence after kidney or liver transplant; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-11-19Clinical Trial Update: Genetics and HIV-1 Protease Inhibitors [Phase 4]
Phase 4 clinical trial update on genetics and HIV-1 protease inhibitors completed with posted results.
-
CLINICAL_TRIALS trial_result · 2019-11-19Clinical Trial Update: Switch to Maraviroc + Integrase Inhibitor [Phase 3]
Phase 3 clinical trial evaluating switching to maraviroc combined with an integrase inhibitor for HIV; trial status completed with results p…